Compare VanEck Gold Miners ETF (GDX) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? VanEck Gold Miners ETF trades at $85.04 (market cap $26.33B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: VanEck Gold Miners ETF is far larger — about 26.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 77 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GDX | MRVI | |
|---|---|---|
Market Cap | $26.33B | $977.37M |
Volume | 31,283,423 | 2,742,564 |
52-Week High | $115.84 | $9.00 |
52-Week Low | $68.28 | $2.83 |
Typical Hold Time | 77 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX trades at $87.24, down 1.46% over the past day, with a neutral technical signal and bearish moving averages. Key support is at $87, with resistance at $89. Financial ratios are unavailable, but recent news highlights institutional selling and comparisons between gold miners and physical gold ETFs. The fund's performance is influenced by gold prices and interest rate trends.
Outlook remains mixed amid gold price volatility and rising rates. Opportunities include potential catch-up if gold rallies, but risks involve further institutional outflows and macroeconomic pressure on metals. Investor sentiment is cautious, with technicals suggesting limited near-term momentum.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
